Alterity Therapeutics Limited — FY2022 Form 20-F
Reporting period: Fiscal year ended June 30, 2022, with comparisons to FY2021 and FY2020. The filing is an annual report, not a quarterly report. Financial statements are prepared under IFRS in Australian dollars (A$). Alterity is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases; it has no commercial product revenue.
Financial performance and position
| Metric (A$ unless noted) | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Product revenue | None | None | No products have been commercialized. |
| Other income | 5.124 million | 4.485 million | Primarily R&D tax incentive income; includes grant income. |
| Research and development expense | 14.746 million | 12.284 million | Up 20%, mainly reflecting commencement of ATH434 Phase 2. |
| General and administrative expense | 5.514 million | 6.938 million | Down 20.5%, including lower share-based compensation and prior-year termination costs. |
| Foreign-exchange gain/(loss) | 2.722 million | (0.297) million | FY2022 gain mainly reflected Australian-dollar depreciation on U.S.-dollar cash. |
| Net loss | (12.847) million | (15.309) million | Loss narrowed; basic and diluted loss per share was A$(0.0053), or 0.53 cents. |
| Operating cash flow | (12.337) million | (17.330) million | Cash used decreased year over year. |
| Cash and cash equivalents | 34.807 million | 28.116 million | Includes a material U.S.-dollar cash balance. |
| Total assets / total liabilities | 41.363 million / 5.894 million | 33.586 million / 3.115 million | Liabilities are principally payables, provisions and lease liabilities; no material borrowings are reported. |
Operating margins are not meaningful because the company has no product sales. FY2022 financing activities generated A$16.305 million net, including A$17.176 million of gross proceeds from ATM share sales and A$0.837 million of issuance costs. Cash also benefited from A$2.813 million of exchange-rate adjustments. The company reported 2.407 billion ordinary shares outstanding at year-end, up from 2.084 billion.
Liquidity, capital and material changes
- Current assets were A$41.144 million and current liabilities A$5.820 million at June 30, 2022. The A$4.669 million R&D tax incentive receivable was a substantial component of receivables.
- Management said available funds were sufficient for planned R&D, the ATH434 Phase 2 trial and working capital for at least 12 months from the report’s issuance. The company nevertheless expects continuing losses and says it will need additional capital for longer-term development.
- ATM proceeds were lower than FY2021 equity proceeds (A$17.176 million versus A$39.237 million gross). Equity financing remains a source of liquidity and may dilute shareholders.
- At year-end, 859.4 million unlisted options were outstanding, including 674.7 million placement-attached options. Exercise could provide capital but increase share count; the filing estimates A$56.6 million of proceeds if all unlisted options were exercised.
- Total comprehensive loss improved from A$15.309 million to A$12.847 million. The change reflected lower G&A expense and a favorable FX swing, partly offset by increased R&D costs. Interest income fell to A$2,504 from A$20,676.
Business, outlook and risks
- Lead program: During FY2022 Alterity commenced a randomized, double-blind, placebo-controlled Phase 2 trial of ATH434 in early-stage multiple system atrophy (MSA), targeting approximately 60 patients over 12 months. The first patient was dosed in New Zealand; the company also received approvals to expand sites to Italy and the UK and was seeking further approvals.
- ATH434 completed Phase 1 studies and has U.S. FDA and European Commission orphan-drug designation for MSA. These are development milestones, not evidence of efficacy in the Phase 2 trial or marketing approval. The bioMUSE natural-history study is intended to inform trial design and biomarkers.
- Outlook: Management expects continued operating losses while research and clinical development continue. The filing gives no revenue or earnings guidance and notes that the timing and cost of development, approvals and commercialization cannot be reliably estimated.
- Funding and execution risks: Additional financing may be unavailable or dilutive; clinical results are uncertain, trials may be delayed, and development depends on research institutions, CROs and contract manufacturers. COVID-19-related restrictions were identified as a potential source of delay and higher costs.
- NASDAQ listing: The company disclosed a minimum-bid-price deficiency notice dated February 23, 2022, with an extension to February 20, 2023 to regain compliance. It said a reverse split could be used if needed; failure to meet listing requirements could result in delisting.
- Tax and FX: The FY2022 R&D tax incentive receivable is subject to eligibility judgments and was identified as a critical audit matter. Separately, the company had objected to the assessment of its FY2020 incentive as a non-refundable offset. U.S.-dollar cash creates material exchange-rate exposure; the company does not use derivatives to hedge it.
- The filing reports no material legal proceedings or contingent liabilities. It reports no dividend and no expectation of dividends in the foreseeable future. COVID-19 had limited operational effect to date, though management warned of possible disruption.
Important facts for investors to verify
- Current ATH434 Phase 2 enrollment, site activation, trial timing, safety findings and any disclosed efficacy or biomarker data.
- Actual cash burn and runway against the stated minimum 12-month outlook, including receipt and continued eligibility of the A$4.669 million R&D tax incentive receivable.
- Further ATM or other financing, share issuance, option exercise and resulting dilution; reconcile the large option overhang with subsequent share-count disclosures.
- NASDAQ bid-price compliance status and any reverse-split action after the filing date.
- Progress and outcome of the objection concerning the FY2020 R&D tax incentive assessment, and any implications for future claims.
- U.S. investor tax treatment: the company states it likely remained a PFIC for some U.S. holders in FY2022; investors should confirm their individual tax position.
Audit and controls: PwC issued an unqualified opinion on the IFRS financial statements. The audit highlighted the R&D tax incentive receivable as a critical audit matter. Management concluded disclosure controls and internal control over financial reporting were effective as of June 30, 2022; the auditor did not express an opinion on internal-control effectiveness.